Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience

The Clinical Problem

When hepatoblastoma recurs or proves refractory to initial therapy, no standard salvage regimen exists 0:12. Treatment decisions rest on institutional experience and extrapolation from limited published data.

What This Cohort Shows

Cincinnati Children's reviewed 30 patients with relapsed or refractory hepatoblastoma—among the largest published cohorts addressing this question 0:17. Overall survival was approximately 50% 0:25. The striking finding: children who received cisplatin as part of salvage therapy had survival near 80%, compared to 25% for those who did not 0:28.

Dr. Skermorn emphasizes the interpretive caution: the association does not prove causality, and these improved survival outcomes may reflect persistent platinum sensitivity or better tumor biology rather than the treatment itself 0:36. The patients who received cisplatin may have been selected for characteristics that independently predicted better outcomes—tumor biology that remained platinum-sensitive, or disease burden amenable to combined-modality treatment.

Most patients underwent additional surgery: liver resection, transplantation, or pulmonary metastasectomy 0:49. Salvage therapy in this cohort was explicitly multimodal 0:57.

What This Means for Decision-Making

The data support considering cisplatin retreatment in carefully selected patients, particularly when surgical consolidation is feasible. The decision requires balancing potential benefit against cumulative toxicity 0:59—ototoxicity and nephrotoxicity accrue with repeated platinum exposure, and the threshold for unacceptable harm varies by patient and family.

The survival difference is large enough to inform practice even if confounded by selection. If a patient's tumor demonstrated initial platinum sensitivity, if surgical options exist, and if toxicity burden remains tolerable, retreatment is reasonable. If the tumor progressed through platinum-based therapy or the patient has already sustained significant toxicity, the case for retreatment weakens.

What Remains Uncertain

This is retrospective, single-institution data. The comparison groups were not randomized. The biological features that predict platinum sensitivity at relapse are not defined. The optimal partner agents, surgical timing, and cumulative dose thresholds remain institutional judgment calls.

What This Episode Covers

Dr. Sophia Skermorn presents Cincinnati Children's retrospective review of 30 patients with relapsed or refractory hepatoblastoma—one of the largest published cohorts addressing salvage therapy in this setting 0:17. The central finding: patients who received cisplatin as part of salvage therapy had survival of approximately 80%, compared to 25% for those who did not receive cisplatin 0:28. No standard salvage regimen currently exists for this population 0:12.

Key Findings

Overall survival for the cohort was approximately 50% 0:25. The survival difference between cisplatin-treated and non-cisplatin-treated patients is substantial, but Dr. Skermorn emphasizes that this association does not establish causality—the improved outcomes may reflect persistent platinum sensitivity or more favorable tumor biology in the patients selected for retreatment rather than proving cisplatin's efficacy in this setting 0:36.

Salvage therapy was multimodal 0:57. Most patients underwent additional surgery: liver resection, liver transplantation, or pulmonary metastasectomy 0:49. The combination of chemotherapy and aggressive surgical management appears central to the approach, not chemotherapy alone.

Clinical Uncertainty

The retrospective design leaves open whether cisplatin retreatment drives the survival benefit or whether it serves as a marker for patients with disease characteristics that make them better salvage candidates. The selection factors that determined which patients received cisplatin versus alternative regimens are not detailed in this presentation.

Implications for Practice

For oncologists and surgeons managing relapsed hepatoblastoma, this series suggests that cisplatin retreatment may be considered in carefully selected patients, particularly when paired with surgical options 0:59. The decision requires balancing potential benefit against cumulative toxicity—a calculation that depends on prior cisplatin exposure, renal function, hearing status, and the feasibility of surgical consolidation. The 50% overall survival in this salvage population 0:25 indicates that cure remains possible after relapse, but the lack of a standard regimen 0:12 means treatment decisions remain individualized and institution-dependent.

What This Episode Covers

Dr. Sophia Skermorn presents a Cincinnati Children's retrospective analysis of 30 patients with relapsed or refractory hepatoblastoma—one of the largest published cohorts addressing salvage therapy in this setting 0:17. The core finding: patients who received cisplatin-based salvage regimens achieved 80% survival compared to 25% in those treated without cisplatin 0:28. Overall cohort survival was approximately 50% 0:25.

Key Clinical Findings

No standard salvage regimen exists for relapsed hepatoblastoma 0:12. In this series, cisplatin retreatment was associated with markedly improved outcomes, but Dr. Skermorn emphasizes that this does not establish causality 0:36. The survival advantage may reflect persistent platinum sensitivity or more favorable tumor biology in patients selected for cisplatin rechallenge rather than proving treatment efficacy 0:36.

Most patients underwent aggressive surgical intervention—liver resection, transplantation, or pulmonary metastasectomy—as part of multimodal salvage therapy 0:49 0:57. The combination of chemotherapy and surgical management appears central to the approach, not chemotherapy alone.

Clinical Uncertainty

The retrospective design leaves the mechanism of benefit unresolved. Whether cisplatin retreatment drives survival improvement or simply identifies patients with chemosensitive disease remains unclear 0:36. Selection bias is inherent: patients deemed fit for cisplatin rechallenge likely differ systematically from those who were not.

Implications for Practice

For pediatric surgical oncologists managing relapsed hepatoblastoma, this series supports considering cisplatin-based salvage regimens in carefully selected patients, particularly when paired with surgical resection or transplantation 0:49 0:57. The decision must account for cumulative platinum toxicity—ototoxicity, nephrotoxicity—against potential survival benefit 0:59. The 80% survival figure applies to a selected subset, not all relapsed patients, and the absence of a standard regimen means treatment remains individualized 0:12 0:28.